This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Therapy With Transdermal Scopolamine and Oral Meclizine

Lenore G. Schmitt, RN; Jane E. Shaw, PhD

Arch Otolaryngol Head Neck Surg. 1986;112(1):88-91.

Abstract
• Twelve healthy subjects received seven-day treatments on a randomized, double-blind, crossover basis, of a transdermal scopolamine system, oral meclizine, and placebo, separated by one-week intervals. Just prior to each treatment, and on days 1 and 7 of each treatment, subjects received two warm (44 °C) caloric irrigations of each external auditory canal. Following each irrigation, subjects rated their vertigo symptoms. Subjects reported on their side effects daily throughout each treatment period. Vertigo symptoms on day 1 of treatment were significantly less with transdermal scopolamine than oral meclizine or placebo and on day 7 were significantly less with both scopolamine and meclizine than the placebo. On day 1, meclizine did not reduce vertigo symptoms significantly when compared with the placebo. Drowsiness was greater with use of oral meclizine than transdermal scopolamine.

(Arch Otolaryngol Head Neck Surg 1986;112:88-91)

Author Affiliations
From the ALZA Corp, Palo Alto, Calif.

Footnotes
Accepted for publication May 24, 1985.

Reprint requests to ALZA Corp, 950 Page Mill Rd, PO Box 10950, Palo Alto, CA 94303-0802 (Dr Shaw).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?